AZOR
LOE Approachingamlodipine besylate and olmesartan medoxomil
NDAORALTABLET
Approved
Sep 2007
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
11
Data completeness
6/8 — Strong
AZOR (amlodipine besylate and olmesartan medoxomil) is . Approved for hypertension, alone, other antihypertensive agents and 2 more indications. First approved in 2007.
Drug data last refreshed 4d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AZOR is a fixed-dose combination antihypertensive containing amlodipine besylate (a calcium channel blocker) and olmesartan medoxomil (an angiotensin II receptor blocker). It treats hypertension by dual mechanism: reducing calcium influx into vascular smooth muscle and blocking angiotensin II vasoconstriction. The combination provides synergistic blood pressure reduction in patients requiring multi-agent therapy.
$3MPart D
LOE ApproachingDeclining
Product is in late-stage lifecycle with minimal Part D spending; teams should expect restructuring as patent expiration approaches and generic competition intensifies.
Mechanism of Action
. Azor is a combination of two antihypertensive drugs: a dihydropyridine calcium antagonist (calcium ion antagonist or slow-channel blocker), amlodipine besylate, and an angiotensin II receptor blocker, olmesartan medoxomil. The amlodipine component of Azor inhibits the transmembrane influx of…
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.